Medical Oncologist
Drug Deep Dive: Imatinib
Imatinib for GIST: — How It Differs From CML Treatment
If you have been prescribed imatinib for GIST, it is the same tablet used in a blood cancer called CML — but it works on a completely different target, your treatment will last a different length of time, and your scans will be read differently. Understanding why helps you know what to watch for.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Different target — In GIST, imatinib blocks a mutated KIT or PDGFRA protein. In CML, it blocks BCR-ABL. Same drug, two different molecular switches.
- Different goal — CML treatment can aim for remission. In metastatic GIST the goal is disease control — stopping usually brings the disease back.
- Scans, not blood tests — GIST response is tracked on CT using criteria that look at tumour density changes, not just size.
- Your mutation type matters — The specific KIT or PDGFRA mutation in your tumour influences the dose and predicts how well imatinib is likely to work.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Imatinib in GIST works by blocking a mutated KIT or PDGFRA protein that is driving tumour growth — a different target from BCR-ABL, which it blocks in CML. The dose, treatment duration, monitoring method, and overall goal all differ between the two diseases. The mutation found in your tumour influences each of these.
What happens when you start imatinib for GIST?
Confirm mutation status
Your tissue is tested for KIT or PDGFRA mutations before treatment begins. The specific mutation found influences the starting dose and tells your oncologist how likely imatinib is to work for your tumour.
Decide the setting
Your oncologist establishes whether imatinib is being given after surgery to reduce the risk of recurrence, or to control disease that cannot be surgically removed. The two settings have different goals and different treatment lengths.
Start the daily tablet
You take imatinib by mouth once a day, with a meal and plenty of water. Your team sets the dose based on your mutation and adjusts it if side effects make it difficult to continue.
Assess response on imaging
CT scans at regular intervals tell your team whether the drug is working. GIST tumours often become less dense on imaging before they shrink, so your team uses criteria that measure density as well as size.
Plan the duration
If imatinib is given after surgery, there will be a planned end date. If it is for disease that cannot be removed, treatment continues as long as it is working — stopping typically leads to rapid disease return.
What should you tell your oncology team before you start imatinib?
- List all medicines, including supplements and herbal remedies — imatinib interacts with several common drugs including blood thinners and antifungals.
- Tell your team about swelling around your eyes, hands or ankles — fluid retention is common and manageable with guidance.
- Report nausea that is not settling — taking imatinib with a full meal usually helps, but your team can adjust things if it persists.
- Tell your team about any unusual bleeding or black stools — these need prompt review.
- Do not stop imatinib without your oncologist's agreement, even if you feel well and your scan looks stable.
- Mention any traditional medicines or supplements you are taking — some affect how imatinib is processed by the body.
Why is imatinib for GIST different from imatinib for leukaemia?
Imatinib blocks tyrosine kinase enzymes — proteins that act as stuck-on switches driving cancer cell growth. In CML, the switch is BCR-ABL, produced by a chromosomal change called the Philadelphia chromosome. In GIST, the switch is almost always a mutated form of KIT, or in a smaller group of patients, PDGFRA.
The treatment goal differs as well. In CML, the aim is deep molecular remission — bringing BCR-ABL to undetectable levels in the blood — and some patients can eventually try a supervised treatment break. In metastatic GIST the aim is disease control. Stopping imatinib almost always leads to rapid disease return, even when scans have looked stable for a long time.
Monitoring is done differently too. CML is followed with blood tests that measure BCR-ABL levels directly. GIST is followed with CT scans, using imaging criteria specifically developed for how this tumour responds.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What do the key terms on your report mean?
- KIT (c-KIT)
- A protein on GIST cells that is mutated to stay permanently active, driving uncontrolled growth. It is the main target of imatinib in GIST and is present in the large majority of cases.
- PDGFRA
- A second protein sometimes mutated in GIST. Most PDGFRA-driven tumours respond to imatinib. A specific variant called D842V typically does not, and a different treatment is used for those.
- Adjuvant imatinib
- Imatinib given after a GIST tumour has been surgically removed, with the aim of reducing the risk of it returning. NCCN and ESMO guidance recommends a defined treatment period for patients with high-risk resected GIST.
- Tyrosine kinase inhibitor (TKI)
- The class of drug that includes imatinib. TKIs block the molecular switches that cancer cells depend on to grow and divide.
- Choi criteria
- Imaging criteria used to judge whether GIST is responding to imatinib. They measure changes in tumour density on CT, not just size, because a responding GIST tumour often becomes less dense before it shrinks.
What does day-to-day life on imatinib for GIST look like?
Most people tolerate imatinib reasonably well. The most common early effects are nausea, swelling around the eyes or ankles, muscle cramps, and tiredness. These often ease over the first few weeks.
You will have CT scans on a schedule your oncologist sets — typically more frequent early in treatment, then less often once your response is established. Unlike CML, there is no blood marker to track between scans.
If imatinib stops working because the tumour has developed a resistance mutation, your oncologist will discuss other tyrosine kinase inhibitors as a next step. Resistance to imatinib does not mean you have run out of options.
Did you know?
Before imatinib, outcomes for patients with advanced GIST were very poor and treatment options were limited. Imatinib was the first targeted treatment approved for this disease and changed the outlook significantly.
NCCN and ESMO both name it as the standard first-line treatment for KIT-positive unresectable or metastatic GIST.
Source: NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma
Explore 75 more Blood Cancer Targeted Medicines topics
Drug Deep Dive: Imatinib (Gleevec)
- Adjuvant Imatinib After GIST Surgery: How Many Years?
- BCR-ABL PCR Monitoring: What 'Log Reduction' and 'MR4.5' Mean
- Can You Ever Stop Imatinib? Treatment-Free Remission Explained
- Diet and Nutrition While on Imatinib
- Fertility, Pregnancy and Contraception on Imatinib
- How Does Imatinib Work? The BCR-ABL and KIT Inhibitor Explained
- How Long Does Imatinib Take to Work?
- Imatinib (Gleevec, Veenat, Imatib): The Complete Patient Guide
- Imatinib Interactions: Paracetamol, Antacids and Herbal Medicines
- Imatinib Myths: Lifelong Dependence, Fertility and Generic Quality
- Imatinib Price in India: Brand, Generic and Monthly Cost
- Imatinib Side Effects: The Complete List and Timeline
- Imatinib Success Rate and Survival: An Honest Look at the Numbers
- Imatinib for GIST: How It Differs From CML Treatment
- Imatinib in Elderly Patients and Those With Other Illnesses
- Imatinib vs Nilotinib vs Dasatinib: Choosing a CML Drug
- Muscle Cramps and Bone Pain on Imatinib: What Actually Helps
- Nausea, Stomach Upset and Weight Gain on Imatinib
- Puffy Eyes and Swollen Legs on Imatinib: Managing Fluid Retention
- Taking Imatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Imatinib
- When Imatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Imatinib? Chronic Myeloid Leukaemia and GIST
- Will Insurance or a Government Scheme Pay for Imatinib?
- Work, Travel and Daily Life on Imatinib
Drug Deep Dive: Ibrutinib (Imbruvica)
- Diarrhoea, Joint Pain and Infection Risk on Ibrutinib
- Diet and Nutrition While on Ibrutinib
- Easy Bruising and Bleeding on Ibrutinib: What Is Normal and What Is Not
- Fertility, Pregnancy and Contraception on Ibrutinib
- How Does Ibrutinib Work? The BTK Inhibitor Explained
- How Long Does Ibrutinib Take to Work?
- How Long Will You Stay on Ibrutinib?
- Ibrutinib (Imbruvica, Ibrutix): The Complete Patient Guide
- Ibrutinib Interactions: Blood Thinners, Antifungals and Fish Oil
- Ibrutinib Myths: Lifelong Treatment, Bruising and 'It's Not Real Treatment'
- Ibrutinib Price in India: Brand, Generic and Monthly Cost
- Ibrutinib Side Effects: The Complete List and Timeline
- Ibrutinib Success Rate and Survival: An Honest Look at the Numbers
- Ibrutinib With Rituximab or Venetoclax: Continuous vs Fixed-Duration Therapy
- Ibrutinib in CLL, Mantle Cell Lymphoma and Waldenstrom's
- Ibrutinib in Elderly Patients and Those With Other Illnesses
- Ibrutinib vs Acalabrutinib vs Zanubrutinib: Comparing BTK Inhibitors
- Palpitations, Atrial Fibrillation and High Blood Pressure on Ibrutinib
- Surgery and Dental Procedures on Ibrutinib: The Bleeding Rule
- Taking Ibrutinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Ibrutinib
- When Ibrutinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Ibrutinib? CLL, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia
- Will Insurance or a Government Scheme Pay for Ibrutinib?
- Work, Travel and Daily Life on Ibrutinib
Drug Deep Dive: Rituximab (MabThera)
- Diet and Nutrition While on Rituximab
- Drug, Food and Supplement Interactions With Rituximab
- Fertility, Pregnancy and Contraception on Rituximab
- Hepatitis B Reactivation and Rituximab: The Test You Must Not Skip
- How Does Rituximab Work? The Anti-CD20 Monoclonal Antibody Explained
- How Long Does Rituximab Take to Work?
- How Long Will You Stay on Rituximab?
- Low Antibodies and Repeated Infections After Rituximab
- MabThera vs Biosimilar Rituximab in India: Cost and Equivalence
- R-CHOP and Other Rituximab Combinations Explained
- Rituximab (MabThera, Ristova and biosimilars): The Complete Patient Guide
- Rituximab Infusion Day: Premedication, Duration and What to Expect
- Rituximab Infusion Reactions: Why the First Infusion Is Different
- Rituximab Maintenance: Two More Years of Infusions, and Why
- Rituximab Myths: Vaccines, Immunity and 'Permanent Damage'
- Rituximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Rituximab Side Effects: The Complete List and Timeline
- Rituximab Success Rate and Survival: An Honest Look at the Numbers
- Rituximab in Elderly Patients and Those With Other Illnesses
- Tests and Monitoring While You Are on Rituximab
- When Rituximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Rituximab? B-Cell Lymphoma and CLL
- Why the Same Drug Treats Arthritis and Lymphoma
- Will Insurance or a Government Scheme Pay for Rituximab?
- Work, Travel and Daily Life on Rituximab
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How long will I take imatinib for GIST?
It depends on why you are taking it. If imatinib is being given after surgery to reduce recurrence risk, NCCN and ESMO guidance recommends a defined course for high-risk resected GIST rather than indefinite treatment — your oncologist will give you a planned end date. If your GIST is metastatic or cannot be surgically removed, treatment continues as long as it is working, because stopping imatinib in that setting almost always leads to rapid disease return regardless of how stable your scans have been.
What happens if imatinib stops working for my GIST?
If imatinib stops controlling your GIST — usually because the tumour has developed a secondary resistance mutation — your oncologist will consider other tyrosine kinase inhibitors. Several options are available for GIST that has progressed on imatinib, and the choice depends on the resistance mutation found and your overall situation. Resistance to imatinib does not mean you have run out of options; it means moving to the next treatment that fits your tumour's current biology.
Is the dose of imatinib the same for GIST as for CML?
Not always. Most patients with KIT-mutated GIST start on the same daily dose used in CML. For a specific mutation called KIT exon 9, NCCN guidance notes that a higher daily dose may produce a better response. Your oncologist sets your dose based on the mutation found in your tumour, not on a single standard figure, and will explain the reasoning when treatment starts.
Can I stop imatinib once my scan looks clear?
In metastatic GIST, no. A stable or clear-looking scan means the drug is working, not that the tumour has gone. Stopping almost always leads to disease return within months. If you are on adjuvant imatinib after surgery, your oncologist will have set a planned end date — complete that course, and do not stop before it without discussion. In both settings, the decision to stop belongs with your oncologist, not with how you feel or what a single scan shows.
Why does my tumour still look the same size if the treatment is working?
GIST responds to imatinib differently from how most tumours respond to chemotherapy. Rather than shrinking, a responding GIST tumour often becomes less dense on CT — the inside changes as cancer cells die, while the outer boundary may stay similar in size. Your team uses Choi criteria, imaging guidelines designed specifically for GIST, which assess both density and size. A tumour that has become significantly less dense and is not growing is generally considered a good response, even if the overall dimensions have not changed much.
What is a KIT exon mutation and why does mine matter?
KIT is a large protein, and mutations in different sections of it — called exons — behave differently. Most GISTs carry mutations in exon 11, which responds well to standard imatinib dosing. Exon 9 mutations also respond to imatinib, but evidence cited in NCCN and ESMO guidance suggests a higher dose may work better for them. Some PDGFRA mutations, particularly the D842V variant, do not respond to imatinib at all and need a different treatment. Knowing which exon is mutated helps your oncologist choose the right dose and anticipate how treatment is likely to go.